This electrochemical platform demonstrates repeatability and selectivity in breast cancer diagnostics by detecting miR-21 and miR-155.
M, with ultralow limits of detection of 62.0 aM for microRNA-21 and 650.0 aM for microRNA-155. The platform demonstrated excellent selectivity, good repeatability and reproducibility, and stable performance for up to 3 weeks. Successful validation in human plasma samples with recovery values between 92% and 119% confirmed the reliability of the proposed system. Overall, this dual-channel biosensor provides a robust and ultrasensitive platform for multiplexed microRNA detection and shows strong potential for early stage breast cancer diagnostics.
No takes yet. Share an insight, caveat, or question.
Alemnezhad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: